Zydus Lifesciences aims for over US$3 billion in revenue by FY26, backed by strong growth and a strategic acquisition of Amplitude Surgical. The company is focusing on innovation-led products and expanding its MedTech business.
Zydus Lifesciences Sets Ambitious FY26 Targets, Acquires Amplitude Surgical
FY26 Revenue: > US$ 3 billion (US$ 3.02bn) FY26 EBITDA: US$ 959 million Reader Takeaway: Strong financial growth and strategic MedTech acquisition position Zydus for future value creation, but pipeline approvals are key. ## What just happened Zydus Lifesciences has outlined key financial targets for FY26, projecting revenue to exceed US$3 billion (US$3.02 billion) and EBITDA to reach US$959 million. Alongside these projections, the company announced the acquisition of Amplitude Surgical, a MedTech platform with approximately €100 million in revenue, strengthening its presence in orthopaedics and interventional fields. ## Why this matters These developments signal Zydus Lifesciences' strategic intent to scale its operations and enhance its revenue streams. The acquisition of Amplitude Surgical diversifies the company's business into the high-growth MedTech sector, complementing its existing Pharma and Consumer Wellness segments. The projected financial growth, with robust CAGRs in revenue, EBITDA, and Adjusted PAT, indicates a sustained performance trajectory. ## The backstory Between FY22 and FY26, Zydus Lifesciences has shown consistent growth, with a Compound Annual Growth Rate (CAGR) of 15.5% in revenue, 26.2% in EBITDA, and 20.1% in Adjusted PAT. The company operates in three global categories: Pharma, Consumer Wellness, and MedTech. In India, its formulations revenue was approximately INR 65,740 million in FY26, with an improved chronic and sub-chronic therapy mix. In North America, Zydus ranks third in the US generics market by prescriptions. ## What changes now The acquisition of Amplitude Surgical positions Zydus Lifesciences as a significant player in the global orthopaedics, interventional cardiology, and nephrology markets. This MedTech platform, with a global distribution network, is expected to contribute substantially to the company's diversified revenue base. Zydus is also advancing its R&D pipeline, with a New Drug Application (NDA) submitted for Saroglitazar for Primary Biliary Cholangitis (PBC) and priority review granted by the USFDA. ## Risks to watch A key risk is the company's reliance on future drug approvals, particularly Saroglitazar's anticipated USFDA approval by Q4FY27. Successful integration of the Amplitude Surgical business and effective execution of its international expansion strategy are crucial for realizing the full potential of these strategic moves. ## Peer comparison Zydus Lifesciences' focus on innovation-led growth and diversification into MedTech aligns with broader industry trends. Companies in the pharmaceutical sector are increasingly looking at specialty drugs, biosimilars, and adjacent healthcare segments like MedTech to drive future growth and enhance margins. ## Context metrics (time-bound) * **FY26 Revenue Target:** Over US$ 3 billion (US$ 3.02bn) * **FY26 EBITDA Target:** US$ 959 million * **FY26 R&D Spend:** US$ 257 million * **Market Cap (as of 21 Aug 2026):** US$ 11.7 billion * **Amplitude Surgical Revenue:** ~€100 million * **Revenue CAGR (FY22-FY26):** 15.5% * **EBITDA CAGR (FY22-FY26):** 26.2% * **Adjusted PAT CAGR (FY22-FY26):** 20.1% ## What to track next Investors will be closely monitoring the USFDA decision on Saroglitazar, the successful integration and performance of Amplitude Surgical, and the continued growth of Zydus's specialty and biosimilar portfolios. The company's ability to maintain its high growth rates and expand its innovation-led offerings will be key indicators.
